Eledon Pharmaceuticals (ELDN) Retained Earnings (2016 - 2017)
Historic Retained Earnings for Eledon Pharmaceuticals (ELDN) over the last 5 years, with Q3 2017 value amounting to -$25.4 million.
- Eledon Pharmaceuticals' Retained Earnings rose 8466.98% to -$25.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$25.4 million, marking a year-over-year increase of 8466.98%. This contributed to the annual value of -$14.4 million for FY2016, which is 8905.19% up from last year.
- As of Q3 2017, Eledon Pharmaceuticals' Retained Earnings stood at -$25.4 million, which was up 8466.98% from -$22.4 million recorded in Q2 2017.
- Eledon Pharmaceuticals' 5-year Retained Earnings high stood at -$14.4 million for Q4 2016, and its period low was -$173.3 million during Q1 2017.
- Its 5-year average for Retained Earnings is -$99.3 million, with a median of -$104.1 million in 2015.
- In the last 5 years, Eledon Pharmaceuticals' Retained Earnings plummeted by 5221.36% in 2015 and then skyrocketed by 8905.19% in 2016.
- Over the past 5 years, Eledon Pharmaceuticals' Retained Earnings (Quarter) stood at -$63.1 million in 2013, then plummeted by 36.95% to -$86.4 million in 2014, then crashed by 52.21% to -$131.4 million in 2015, then soared by 89.05% to -$14.4 million in 2016, then tumbled by 76.48% to -$25.4 million in 2017.
- Its Retained Earnings stands at -$25.4 million for Q3 2017, versus -$22.4 million for Q2 2017 and -$173.3 million for Q1 2017.